New targeted treatment for ovarian cancer
Official title: Novel targeted therapy for treating Ovarian Cancer
Funded at University of Texas Hlth Science Center · NIH-10893972 · Data updated 2026-11-12
This study is working on a new treatment for ovarian cancer that could help patients who struggle with the usual therapies, by using a special drug called EC359 to target the cancer cells more effectively and hopefully improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $639,397 |
| NIH project number | 5R01CA266970-03 |
| Project ID | NIH-10893972 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have experienced recurrence or resistance to standard therapies.
✕Less likely to help
Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research aims to develop a novel targeted therapy for ovarian cancer, which is known for its high recurrence rates and resistance to standard treatments. The approach involves creating a small molecule inhibitor, EC359, that targets specific proteins involved in cancer cell survival and growth. By collaborating with a biotech company, the research team will synthesize this inhibitor and test its effectiveness in promoting cancer cell death and reducing cancer stem cells. Patients may benefit from a more effective treatment option that addresses the challenges of chemotherapy resistance.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, potentially improving survival rates.
How similar studies have gone: Other research has shown promise in developing targeted therapies for cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Vadlamudi, Ratna K — University of Texas Hlth Science Center
- Study coordinator: Vadlamudi, Ratna K
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapy to treat ovarian cancer by promoting cancer cell death
A new, targeted therapy called EC359 aims to kill ovarian cancer cells and cancer stem cells, potentially improving outcomes for patients who have recurrent, treatment-resistant disease.
-
Fluorescent-guided laparoscopy with light-activated chemotherapy for tiny ovarian cancer spread
This uses a fluorescent agent to make tiny ovarian cancer nodules glow during laparoscopy and a near-infrared light to trigger local release of chemotherapy at those spots for people with advanced epithelial ovarian cancer.
-
A new targeted treatment for ovarian cancer
This research aims to develop a brand new medicine to help patients with ovarian cancer, especially those whose cancer has come back or stopped responding to current treatments.
-
Improving detection and treatment of small ovarian cancer tumors
This study is looking for ways to find and treat tiny tumors in women with advanced ovarian cancer using special imaging and a light-activated drug, which could lead to better results and fewer side effects than regular chemotherapy.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.